Drug Trial Radar · NCT05525715
A Study of QY201 Tablet in Subjects With Moderate to Severe Atopic Dermatitis
Last checked: Nov 19, 2026Latest source record: Sep 2, 2022 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Status unknown
Enrollment
260
Planned (sponsor's estimate)
Start
Oct 2022
Primary completion
Dec 2025
Study completion Dec 2025
Sponsor
- Lead sponsor
- E-nitiate Biopharmaceuticals (Hangzhou) Co., Ltd.Industry
- Sponsor type
- Industry
- First posted
- Sep 2, 2022
Design
- Study type
- Interventional
- Phase
- Phase 1 / Phase 2
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Triple (participant, investigator, outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years, up to 75 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This is a phase Ib/II, randomized, double-blind, placebo-controlled, parallel, multicenter study of a certain phase to evaluate the efficacy, safety, and pharmacokinetic characteristics of QY201 tablet in subjects in moderate to severe atopic dermatitis
Conditions
- Atopic Dermatitis
Interventions
2mg QY201 tablets or 2mg QY201 placebo,BIDDrug
2mg QY201 tablets or 2mg QY201 placebo,BID
5mg QY201 tablets or 5mg QY201 placebo,BIDDrug
5mg QY201 tablets or 5mg QY201 placebo,BID
10mg QY201 tablets or 10mg QY201 placebo,QDDrug
10mg QY201 tablets or 10mg QY201 placebo,QD
10mg QY201 tablets or 10mg QY201 placebo,BIDDrug
10mg QY201 tablets or 10mg QY201 placebo,BID
15mg QY201 tablets or 15mg QY201 placebo,BIDDrug
15mg QY201 tablets or 15mg QY201 placebo,BID
20mg QY201 tablets or 20mg QY201 placebo,BIDDrug
20mg QY201 tablets or 20mg QY201 placebo,BID
5mg QY201 tablets,BIDDrug
5mg QY201 tablets,BID
10mg QY201 tablets,BIDDrug
10mg QY201 tablets,BID
20mg QY201 tablets,BIDDrug
20mg QY201 tablets,BID
QY201 placebo,BIDDrug
QY201placebo,BID
Primary outcomes
What the sponsor says the trial is designed to measure.
- Number of Participants With Treatment Emergent Adverse Events (AEs)- Phase ⅠbTime frame: From the first administration to 28 days after the last administration of the study drug
- Percentage of Participants Achieving >=75% Improvement From Baseline in Eczema Area and Severity Index (EASI75) Response at Week 12- Phase ⅡTime frame: Week 12
Locations
No sites are listed on the registry yet.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.